Get started
RocketTickers

FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifical

Long
RocketTickers  
NASDAQ:GBT   None
Beyond Technical Analysis
3
0
beyondta
GBT: Global Blood Therapeutics, Inc.
2019-11-25 16:03:11
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.